scholarly journals Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial

Thyroid ◽  
2017 ◽  
Vol 27 (9) ◽  
pp. 1135-1141 ◽  
Author(s):  
Naomi Kiyota ◽  
Bruce Robinson ◽  
Manisha Shah ◽  
Ana O. Hoff ◽  
Matthew H. Taylor ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Efficacy And Safety ◽  
Select Trial

scholarly journals Neoadjuvant Therapy in Differentiated Thyroid Cancer

2016 ◽  
Vol 2016 ◽  
pp. 1-8 ◽  
Author(s):  
Rajan P. Dang ◽  
Daniel McFarland ◽  
Valerie H. Le ◽  
Nadia Camille ◽  
Brett A. Miles ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Neoadjuvant Therapy ◽  
Differentiated Thyroid Cancer ◽  
Potential Role ◽  
Kinase Inhibitors ◽  
Tracheal Resection ◽  
Complete Surgical Resection ◽  
Select Trial ◽  
Short Time

Objectives. Invasion of differentiated thyroid cancer (DTC) into surrounding structures can lead to morbid procedures such as laryngectomy and tracheal resection. In these patients, there is a potential role for neoadjuvant therapy.Methods. We identified three studies involving the treatment of DTC with neoadjuvant chemotherapy: two from Slovenia and one from Japan.Results. These studies demonstrate that in selected situations, neoadjuvant chemotherapy can have a good response and allow for a more complete surgical resection, the treatment of DTC. Additionally, the SELECT trial shows that the targeted therapy lenvatinib is effective in the treatment of DTC and could be useful as neoadjuvant therapy for this disease due to its short time to response. Pazopanib has also demonstrated promise in phase II data.Conclusions. Thus, chemotherapy in the neoadjuvant setting could possibly be useful for managing advanced DTC. Additionally, some of the new tyrosine kinase inhibitors (TKIs) hold promise for use in the neoadjuvant setting in DTC.

Prognostic Value of Lymphocyte-to-Monocyte Ratio for Japanese Patients With Differentiated Thyroid Cancer Treated With Sorafenib Therapy

2021 ◽  
Vol 1 (5) ◽  
pp. 491-498
Author(s):  
SHOGO NAKAMOTO ◽  
MASAHIKO IKEDA ◽  
SHINICHIRO KUBO ◽  
MARI YAMAMOTO ◽  
TETSUMASA YAMASHITA ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Prognostic Value ◽  
Differentiated Thyroid Cancer ◽  
Median Overall Survival ◽  
Japanese Patients ◽  
Efficacy And Safety ◽  
Systemic Immunity ◽  
Lymphocyte To Monocyte Ratio ◽  
Cell Counts ◽  
Sorafenib Therapy

Background/Aim: We investigated the efficacy and safety of sorafenib in Japanese patients and the prognostic value of systemic immunity markers for predicting clinical outcomes after sorafenib therapy in patients with radioiodine refractory differentiated thyroid cancer (RR-DTC). Patients and Methods: We retrospectively evaluated 26 patients with RR-DTC who underwent sorafenib therapy between July 2014 and December 2020. The systemic immunity markers were calculated from blood cell counts. Results: The median overall survival (OS) was 2,002 days, and the clinical benefit rate was 80.8%. The high lymphocyte-to-monocyte ratio (LMR) group had significantly longer OS than the low LMR group (hazard ratio=0.21; 95% confidence interval=005-0.88; log-rank p=0.019). Adverse events observed in this study were acceptable, and no new safety signals associated with sorafenib were found. Conclusion: Sorafenib therapy is efficacious and safe for Japanese patients with RR-DTC, and baseline LMR may be useful as a sorafenib therapy prognostic marker.

Efficacy and safety of lenvatinib for the treatment of patients with 131I-refractory differentiated thyroid cancer with and without prior VEGF-targeted therapy.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 6013-6013 ◽  
Author(s):  
Kate Newbold ◽  
Rossella Elisei ◽  
Matthew Hiram Taylor ◽  
Monika K. Krzyzanowska ◽  
Manisha H. Shah ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Targeted Therapy ◽  
Differentiated Thyroid Cancer ◽  
Efficacy And Safety

scholarly journals Recombinant human thyrotropin in radioiodine diagnostics and radioiodine ablation of patients with well-differentiated thyroid cancer: the first experience in Russia

2018 ◽  
Vol 12 (3) ◽  
pp. 128-139
Author(s):  
Ivan I. Dedov ◽  
Pavel O. Rumyantsev ◽  
Ksenia S. Nizhegorodova ◽  
Konstantin Y. Slashchuk ◽  
Valentina S. Yasyuchenya ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Side Effects ◽  
Thyroid Hormones ◽  
Differentiated Thyroid Cancer ◽  
Radioiodine Therapy ◽  
Thyroid Stimulating Hormone ◽  
Efficacy And Safety ◽  
Post Surgery ◽  
Radioiodine Ablation ◽  
Well Differentiated

Background. Traditional endogenous stimulation of thyroid-stimulating hormone (TSH) by means of long-term withdrawal of thyroid hormones for radioiodine diagnostics and radioiodine therapy causes severe hypothyroidism, which worsens patients’ general well-being and may lead to side effects and cause tumor growth and dissemination. Exogenous stimulation with recombinant human TSH (rh-TSH, thyrotropin-alfa) causes short-term increases in TSH levels and does not have the above-mentioned side effects. Purpose. To estimate the efficacy and safety of rh-TSH in preparation of patients with well-differentiated thyroid cancer for radioiodine diagnostics and radioiodine therapy. Methods. We conducted an interventional single-center prospective unblinded uncontrolled study of the efficacy and safety of thyrotropin-alfa to prepare patients with well-differentiated thyroid cancer to radioiodine diagnostics and post-surgery radioiodine ablation. The study included 88 patients with well-differentiated thyroid cancer: 54 patients were prepared for post-surgery radioiodine ablation; 34 patients – for radioiodine diagnostics to evaluate combined treatment efficacy and exclusion of tumor recurrence. The level of TSH, thyroglobulin, antibodies to thyroglobulin, whole body scintigraphy, and side effects were measured during exogenous stimulation with thyrotropin-alfa. Results. The level of TSH reached or exceed the target level (30 mIU/ml) 24 hours after the first injection of recombinant thyrotropin-alfa in 86% of patients; after 48 hours in 100%, the level exceeding 100 IU/ml was observed in 66 (75.1%) patients. The maximum levels of thyroglobulin and antibodies to thyroglobulin were reached 72 and 48 hours after the first injection, respectively. The injections of thyrotropin-alfa were well-tolerated by the patients. In the group for radioiodine diagnostics 2 (5.8%) patients complained of fatigue, 1 (2.9%) patient had signs of dyspeptic disorder, while in the group for radioiodine ablation 4 (7.4%) patients complained of fatigue, 1 (1.8%) patient had marked memory problems that disappeared later (they must have been caused by the patient’s advanced age (82 years)). Conclusions. Exogenous recombinant human thyroid-stimulating hormone (thyrotropin-alpha) is highly effective in preparation of patients with well-differentiated thyroid cancer for radioiodine diagnostics and radioiodine ablation. It does not have side effects, which are typical of withdrawal of thyroid hormones. The levels of thyroglobulin and antibodies to thyroglobulin measured 72 hours after the first injection of thyrotropin-alfa have the biggest diagnostic informative value.

Sign in / Sign up

Export Citation Format

Share Document